

**AWARD NUMBER: W81XWH-16-1-0158**

**TITLE:** Defining Hepatocellular Carcinoma Subtypes and Treatment Responses in Patient-Derived Tumorgrafts

**PRINCIPAL INVESTIGATOR:** Akbar Waljee, MD, MSc

**RECIPIENT: Veteran's Education and Research Association of Michigan (VERAM)**  
2215 Fuller Rd Rear  
Ann Arbor, MI 48105-23032

**REPORT DATE:** OCTOBER 2020

**TYPE OF REPORT:** Final Report

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command      Fort Detrick,  
Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

<b>REPORT DOCUMENTATION PAGE</b>			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
<b>1. REPORT DATE</b> OCTOBER 2020		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED</b> 30 Sept 2016 - 12 JUN 2020	
<b>4. TITLE AND SUBTITLE</b>  Defining Hepatocellular Carcinoma Subtypes and Treatment Responses in Patient-Derived Tumorgrafts			<b>5a. CONTRACT NUMBER</b>		
			<b>5b. GRANT NUMBER</b> W81XWH-16-1-0158		
			<b>5c. PROGRAM ELEMENT NUMBER</b>		
<b>6. AUTHOR(S)</b> Hao Zhu, Amit Singal, Adam Yopp, Daniel Siegwart, Akbar Waljee  E-Mail: Hao.Zhu@utsouthwestern.edu; amit.singal@utsouthwestern.edu; awaljee@med.umich.edu			<b>5d. PROJECT NUMBER</b>		
			<b>5e. TASK NUMBER</b>		
			<b>5f. WORK UNIT NUMBER</b>		
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  UT Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-9020			Veteran's Education and Research Association of Michigan (VERAM) 2215 Fuller Rd Rear Ann Arbor, MI 48105-23032		
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>		
			<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>		
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited			<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>		
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Hepatocellular carcinoma (HCC) is the 6 <sup>th</sup> most common cancer and 3 <sup>rd</sup> leading cause of cancer-related death worldwide. We know that HCC subtypes exist because clear clinical, radiographic, and histological differences between patients with HCC are observed. In this study we investigated distinct subtypes of HCC using a mouse-human chimeric Patient Derived Xenograft (PDX) approach. We have performed a large effort to implant more than 100 tumors from human HCC patients from Texas. We have established the protocol and the results have taught us that engraftment using a variety of transplantation techniques will result in a 25-30% engraftment efficiency for early stage surgical tumors. We have established eight new human HCC PDX models that will be highly relevant for therapeutic and biological studies. These represent North American HCCs, including some patients with intermediate/advanced stage HCC, which is a unique resource for the field.					
<b>15. SUBJECT TERMS</b> HCC, patient derived xenografts, siRNA, mouse models of cancer.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	15	<b>19b. TELEPHONE NUMBER</b> (include area code)

## TABLE OF CONTENTS

	<u>Page No.</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	10
5. Changes/Problems	10
6. Products	11
7. Participants & Other Collaborating Organizations	13
8. Special Reporting Requirements	15
9. Appendices	15

- 1. INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

Hepatocellular carcinoma (HCC) is the 6th most common cancer and 3rd leading cause of cancer-related death worldwide. In the US, its incidence has doubled over the past two decades due to the growing number of patients with hepatitis C virus (HCV) and/or non-alcoholic steatohepatitis (NASH) (El-Serag, 2004, 2012). We know that HCC subtypes exist because clear clinical, radiographic, and histological differences between patients with HCC are observed (Yopp et al., 2015). In this study we proposed to investigate distinct subtypes of HCC using a mouse-human chimeric Patient Derived Xenograft (PDX) approach. We aim to analyze and functionalize early and advanced stage HCC tumors with a large and representative cohort of patient derived xenograft (PDX) models. Our hypothesis is that HCC is poorly understood because tissue has been obtained from early HCC but not advanced cases. Biological subclasses of HCCs that behave differently in terms of natural history, prognosis and treatment response have not been categorized and/or functionally analyzed. Our team will use human-mouse PDX models to uncover novel biology and establish a platform to study experimental therapeutics.

- 2. KEYWORDS:** Provide a brief list of keywords (limit to 20 words).

HCC, patient derived xenografts, siRNA, mouse models of cancer.

- 3. ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

**What were the major goals of the project?**

For reference, the complete Statement of Work (SOW) is presented below with detail of Aims, Major Tasks, and Subtasks with Anticipated time lines. The column titled “Progress” indicates portion of the Major Task and related Sub-tasks completed.

<b>Site 1:</b>	UT Southwestern Medical Center	<b>Site 2:</b>	Ann Arbor Veterans Affairs Healthcare System
	5323 Harry Hines Blvd		2215 Fuller Rd
	Dallas, TX 75390		Ann Arbor, MI 48105
	Initiating PI: Dr. Hao Zhu Partnering PIs: Drs. Amit Singal; Adam Yopp; Daniel Siegart		Partnering PI: Dr. Waljee

Specific AIM 1: Determine if early vs. advanced HCCs have distinct cell-intrinsic biology in PDX engraftment assays	Timeline in months	Site 1 (Initiating PI)	Site 2 (Partnering PI)	Progress (Percent Complete or Completion Date)
<b>Major Task 1:</b> Expand and characterize PDX models derived from surgical and biopsy HCC specimens				

Pre-task: Allow time to receive the regulatory approval for animal use (IACUC and DoD ACURO)	1-3	Drs. Yopp, Singal, and Zhu		100 % complete November 2016
Pre-task 2: Allow time to receive the regulatory approval for the Human Anatomical Substance use (IRB and DoD HRPO).	1-3	Drs. Yopp, Singal, and Zhu		100 % complete November 2016
Subtask 1: Continue to implant 40 surgical HCC specimens in the subcutaneous space and livers of NSG mice	0-12	Drs. Yopp and Zhu		100% complete Sep 2018
Subtask 2: Continue to implant 25 biopsy samples from intermediate and advanced HCC cases in the subcutaneous space and livers of NSG mice	0-12	Drs. Yopp, Singal, and Zhu		100% complete Sep 2018
Subtask 3: Harvest primary PDX tumors, establish PDX bank, and passage into additional NSG mice	6-18	Drs. Yopp and Zhu		100% complete Oct 2018
Subtask 4: Characterize tumor architecture, histology, growth, invasiveness, and paraneoplastic features of tumors that engraft, and determine if the grafts resemble or deviate from original tumors (surgical or biopsy specimens)	6-24	Drs. Yopp and Zhu		100% complete Sept 2018
Subtask 5: Obtain genomic data from PDX grafts to determine if they resemble or deviate from original tumors (surgical or biopsy specimens)	12-30	Drs. Yopp, Singal, and Zhu		100% complete June 2018
<b>Major Task 2:</b> Compare biological and genetic features (stage, survival, progression) of early vs. non-early HCCs				
Subtask 1: Compare biological features of the tumors that engraft vs. those that do not, and determine if there is a difference between PDX made from early surgical or more advanced biopsy specimens	6-24	Drs. Yopp and Zhu		100% complete April 2019
Subtask 2: Compare patient clinical features (stage, survival, progression) of specimens that engraft versus not engraft and determine if engraftment can predict clinical outcomes	6-18	Drs. Singal,	Drs. Wajlee	100% complete October 2018
Subtask 3: Analyze genomic data to survey genetic landscape of PDX population that successfully engrafts and identify genetic drivers of engraftment	12-36	Drs. Singal and Zhu	Drs. Wajlee	100% complete October 2018

<i>Milestone #1: Co-author manuscript on biology and genomics of HCC PDX models</i>	12-24	Drs. Zhu, Singal, and Yopp	Drs. Wajlee	100% complete July 2019
<b>Specific AIM 2: Determine the efficacy of small RNA therapeutics against the <i>LIN28B/LET-7</i> pathway in PDXs activating this oncogenic pathway</b>	<b>Timeline</b>	<b>Site 1</b> (Initiating PI)	<b>Site 2</b> (Partnering PI)	
<b>Major Task 1: Identify and deliver small RNAs to target PDX populations</b>				
Subtask 1: Evaluate and optimize custom dendritic nanoparticle delivery to PDX tumors	0-12	Drs. Zhu and Siegwart		100% complete Dec 2018
Subtask 2: Formulate and optimize siRNA and microRNA containing dendritic nanoparticles to ensure that successful modulation of LIN28B and or LET-7 is achieved in PDX models.	6-24	Dr. Siegwart		100% Sept 2019
Subtask 3: Define HCC PDX models that overexpress MYC or LIN28B and those that suppress LET-7 family microRNAs	6-24	Drs. Singal and Zhu		Incomplete, discontinued
Subtask 4: Therapeutically deliver siRNAs or microRNAs in dendritic nanoparticles to mice harboring these PDX models	12-36	Dr. Siegwart		100% complete (performed in analogous models) June 2020
<b>Major Task 3: Define response to small RNAs in target PDX populations</b>				
Subtask 1: Determine response to small RNA therapies using luciferase and CT imaging	6-30	Dr. Siegwart		100% complete (performed in analogous models)
Subtask 2: Define histological response and intermediate markers of tumor biology (Ki67, apoptosis, necrosis)	12-36	Dr. Siegwart		75% complete (performed in analogous models)
<i>Milestone #2: Co-author manuscript about therapeutic efficacy of small RNA therapy in HCC PDX models</i>	24-36	Drs. Zhu and Siegwart		Not completed
<b>Specific AIM 3: Define targeted therapy responders with HCC-PDX patient avatars and use to identify predictive biomarkers</b>	<b>Timeline</b>	<b>Site 1</b> (Initiating PI)	<b>Site 2</b> (Partnering PI)	

<b>Major Task 1:</b> Define PDX models that show partial response, stable disease, and progressive disease to targeted therapies				
Subtask 1: Characterize tumors for growth, histology, vascular invasion, metastasis, proliferation and apoptosis after treatment	12-36	Drs. Zhu, Yopp, and Singal		100% complete Oct 2018
Subtask 2: Perform exome and RNA-expression sequencing for top responders and non-responders for each group to determine mechanistic basis of response	18-36	Drs. Singal and Zhu	Dr. Waljee	100% complete July 2019
<b>Major Task 2:</b> Establish predictive biomarkers for response to treatment				
Subtask 1: Use machine learning methods to identify clinical and genetic factors associated with response to targeted therapies	18-36	Drs. Yopp, and Singal	Dr. Waljee	100% complete Oct 2018
Subtask 2: Derive and internally validate predictive model using factors significantly associated with targeted therapy response	24-36	Dr. Singal	Dr. Waljee	100% complete July 2019
Milestone #3: Co-author manuscript on HCC PDX treatments and predictive modeling results	24-36	Drs. Zhu, Yopp, and Singal	Dr. Waljee	Will not continue July 2019

### What was accomplished under these goals?

<b>Specific AIM 1: Determine if early vs. advanced HCCs have distinct cell-intrinsic biology in PDX engraftment assays</b>
<b>Major Task 1:</b> Expand and characterize PDX models derived from surgical and biopsy HCC specimens
<b>Subtask 1: Implant surgical HCC specimens in the subcutaneous space and livers of NSG mice.</b> This task has been completed by Drs. Singal, Yopp, and Zhu.
<b>Subtask 2: Continue to implant 25 biopsy samples from intermediate and advanced HCC cases in the subcutaneous space and livers of NSG mice.</b> This subtask has been completed by Drs. Singal, Yopp, and Zhu.
<b>Subtask 3: Harvest primary PDX tumors, establish PDX bank, and passage into additional NSG mice.</b> This task has been completed by Drs. Singal, Yopp, and Zhu.
<b>Subtask 4: Characterize tumor architecture, histology, growth, invasiveness, and paraneoplastic features of tumors that engraft, and determine if the grafts resemble or deviate from original tumors (surgical or biopsy specimens).</b> This subtask is complete.

**Subtask 5: Obtain genomic data from PDX grafts to determine if they resemble or deviate from original tumors (surgical or biopsy specimens).** This has been completed.

**Major Task 2:** Compare biological and genetic features (stage, survival, progression) of early vs. non-early HCCs

**Subtask 1: Compare biological features of the tumors that engraft vs. those that do not, and determine if there is a difference between PDX made from early surgical or more advanced biopsy specimens**

This has been completed by Drs. Singal, Yopp, and Zhu.

**Subtask 2: Compare patient clinical features (stage, survival, progression) of specimens that engraft versus not engraft and determine if engraftment can predict clinical outcomes**

This has been completed by Drs. Singal, Yopp, and Zhu.

**Subtask 3: Analyze genomic data to survey genetic landscape of PDX population that successfully engrafts and identify genetic drivers of engraftment**

Dr. Waljee's team considered a variety of gene selection methods, including (1) logistic regression model with lasso regularization, (2) logistic regression model with elastic net regularization, (3) nearest shrunken centroid (NSC) method, and (4) adaptive hierarchically penalized NSC (AHP-NSC). This task was completed.

**Milestone #1: Co-author manuscript on biology and genomics of HCC PDX models**

The manuscript has been published by Drs. Singal, Yopp, Waljee, and Zhu. Zhu M et al., Hepatology. 2020 Jan 3 (EPub ahead of print). Information from this project also contributed to a second manuscript, recently published at Hepatology by Drs. Singal, Zhu, and Yopp. These papers are listed in a below section.

**Subtask 1: Compare biological features of the tumors that engraft vs. those that do not, and determine if there is a difference between PDX made from early surgical or more advanced biopsy specimens**

This was completed by Drs. Singal, Yopp, Waljee, and Zhu.

**Specific AIM 2 (Determine the efficacy of small RNA therapeutics against the LIN28B/LET-7 pathway in PDXs activating this oncogenic pathway).**

**Major Task 1:** Identify and deliver small RNAs to target PDX populations

**Subtask 1: Evaluate and optimize custom dendritic nanoparticle delivery to PDX tumors**

This has been completed by Drs. Zhu and Siegwart.

**Subtask 2: Formulate and optimize siRNA and microRNA containing dendritic nanoparticles to ensure that successful modulation of LIN28B and or LET-7 is achieved in PDX models.**

This has been completed by Dr. Siegwart.

**Subtask 3: Define HCC PDX models that overexpress MYC or LIN28B and those that suppress LET-7 family microRNAs**

We did not find any PDXs that were overexpressing LIN28B, thus we have altered the targets for this subtask. Instead we have used an siRNA to target ANLN, which is a gene required for cytokinesis. We have previously shown in other work that this is a good therapeutic target for liver cancer. This work is a collaboration with Alnylam. We now have a few candidate siRNAs worked well in human cell lines. In the future, we are planning on using the HCC PDX lines to test the ANLN siRNAs in vivo, either in orthografts or in xenografts. This will require additional studies funded by other grants.

**Subtask 4: Therapeutically deliver siRNAs or microRNAs in dendritic nanoparticles to mice harboring these PDX models**

This was done by Dr. Siegwart. In a previous report, we described our discovery of hepatocyte-specific and Kupffer cell-specific dendrimer lipid nanoparticles (DLNPs). We made the exciting observation that dendrimer chemistry can control cellular tropism within the liver. This has been completed using analogous models. We published two manuscripts concerning optimizing dendritic nanoparticles to deliver RNAs to the liver relating to this subtask and other aims/subtasks of the overall grant: (1) Cheng et al. Advanced Materials, 2018, 30, 1805308. (2) Zhou et al. Molecular Pharmaceutics, 2020, 17, 5, 1575-1585.

**Major Task 3:** Define response to small RNAs in target PDX populations

<p><b>Subtask 1: Determine response to small RNA therapies using luciferase and CT imaging</b>  Drs. Zhu, Yopp, and Siegwart are working on this with ANLN siRNAs. We have candidate siRNA of ANLN that worked well in human cell lines. Dr. Siegwart has also determined responses using luciferase imaging for MYC and PD-L1 therapies in analogous HCC mouse models.</p>
<p><b>Subtask 2: Define histological response and intermediate markers of tumor biology (Ki67, apoptosis, necrosis)</b>  We have obtained ANLN siRNAs from Alnylam to perform these experiments, but at this point these cannot be completed without additional funding.</p>
<p><b>Specific AIM 3: Define targeted therapy responders with HCC-PDX patient avatars and use to identify predictive biomarkers</b>  There were not enough PDXs to do this. Discontinued.</p>
<p><b>Major Task 1: Define PDX models that show partial response, stable disease, and progressive disease to targeted therapies</b></p>
<p><b>Subtask 1: Characterize tumors for growth, histology, vascular invasion, metastasis, proliferation and apoptosis after treatment</b>  This was performed by Drs. Zhu, Yopp, and Siegwart. We have performed selected drug studies in the PDX models so this has been completed. We have also started testing experimental drugs that target telomere elongation. This is a drug developed by Jerry Shay at UTSW. So far, some PDXs have responded to these drugs when in combination with immunotherapy. We have added more PDX lines to test the telomere elongation targeting experimental drugs.</p>
<p><b>Subtask 2: Perform exome and RNA-expression sequencing for top responders and non-responders for each group to determine mechanistic basis of response</b>  This was performed by Drs. Zhu, Waljee, and Siegwart. This has not been completed because the numbers of PDXs and therefore responder/non-responder cohorts are too small for this type of analysis. This subtask has been discontinued.</p>
<p><b>Major Task 2: Establish predictive biomarkers for response to treatment</b></p>
<p><b>Subtask 1: Use machine learning methods to identify clinical and genetic factors associated with response to targeted therapies</b>  This has not been completed because we do not have enough responders and non-responders. This subtask has been discontinued.</p>
<p><b>Subtask 2: Derive and internally validate predictive model using factors significantly associated with targeted therapy response</b>  This has not been completed and will be discontinued.</p>
<p><b>Milestone #3: Co-author manuscript on HCC PDX treatments and predictive modeling results</b>  This has not been completed. Other work involving PDX models will be pursued and published in the near future.</p>

**What opportunities for training and professional development has the project provided?**

Nothing to report during this period.

**How were the results disseminated to communities of interest?**

Several papers have been published.

### What do you plan to do during the next reporting period to accomplish the goals?

Nothing to report.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

### What was the impact on the development of the principal discipline(s) of the project?

The major impact at this point is that we have performed a large effort to implant 102 tumors from human HCC patients from Texas. We have established the protocol and the results have taught us how efficient this process will be. We have established 8 new human HCC PDX models that will be highly relevant for therapeutic and biological studies. These represent North American HCCs, including some patients with intermediate/advanced stage HCC, which is a unique resource for the field. We have found that increasing the rate of engraftment with partial hepatectomy or mouse models of chronic liver disease helps to make the growth and engraftment of the tumors more efficient. We will be able to use these models to evaluate experimental therapeutics, in the form of small molecules or small interfering RNAs.

Several outside groups have contacted us to test their therapies on our models. We will collaborate with them and share our reagents.

We demonstrated HCC can have variable tumor biology, showing some tumors are fast growing and others are indolent. We have shown this in mice and then demonstrated this is also true using clinical data in humans. This was first evaluated using local data combined in a multi-site retrospective study we led. Recently, we have similarly shown this to be true in a systematic review of the literature on tumor biology in HCC (Nathani et al, in press at Gut). The PDX and organoid models serve as a good system to evaluate biological drivers of tumor biology in the future.

### What was the impact on other disciplines?

Nothing to report

### What was the impact on technology transfer?

We have set up several collaborations with Cedars Sinai Medical Center and Baylor Medical Center, where labs have requested our PDX models.

### What was the impact on society beyond science and technology?

Nothing to report

5. **CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants

Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:

**Changes in approach and reasons for change**

Nothing to report

**Actual or anticipated problems or delays and actions or plans to resolve them**

None

**Changes that had a significant impact on expenditures**

Nothing to report

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

**Significant changes in use or care of human subjects**

Nothing to report.

**Significant changes in use or care of vertebrate animals.**

None

**Significant changes in use of biohazards and/or select agents**

Nothing to report

**6. PRODUCTS:**

- **Publications, conference papers, and presentations**  
Report only the major publication(s) resulting from the work under this award.

## Journal publications.

1. Zhu M, Li L, Lu T, Yoo H, Zhu J, Gopal P, Wang SC, Porempka MR, Rich NE, Kagan S, Odewole M, Renteria V, Waljee AK, Wang T, Singal AG, Yopp AC, Zhu H. 2020. Uncovering biological factors that regulate hepatocellular carcinoma growth using patient derived xenograft assays. *Hepatology*. Epub. PMID: 31899548.
2. Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S, Wei Y, Zhu H, Siegwart DJ. 2018. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of Hepatorenal Tyrosinemia Type I. *Advanced Materials*. 30, 1805308.
3. Rich NE, John BV, Parikh, ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp A, Hoshida Y, Yao FY, Marrero JA, Singal AG. 2020. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. *Hepatology*. Epub. PMID: 32017165.
4. Zhou K, Johnson LT, Xiong H, Barrios S, Minnig JT, Yan Y, Abram B, Yu X, Siegwart DJ. 2020. The hydrophobic domain structure of linear-dendritic poly(ethylene glycol) lipids affects RNA delivery of lipid nanoparticles." *Molecular Pharmaceutics*, 17, 1575.

## Books or other non-periodical, one-time publications.

Nothing to report

## Other publications, conference papers, and presentations.

Nothing to report

- **Website(s) or other Internet site(s)**

Nothing to report

- **Technologies or techniques**

These techniques have been described above and will be reported to the community when a manuscript is published. While PDX models of cancer are commonly generated, there are specific approaches that were optimized in the course of this project and they were described in Zhu et al, *Hepatology* 2019.

- **Inventions, patent applications, and/or licenses**

Nothing to report.

- **Other Products**

Data or databases: We continue to collect patient data in a clinical database. Biospecimen collections: We have a human HCC biospecimen and PDX collection. Research material: We have established live mice carrying human HCC PDXs.
---

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

Name: Hao Zhu

Project Role: Lead PI

Researcher Identifier (e.g. ORCID ID): 0000-0002-8417-9698

Nearest person month worked: 45

Contribution to Project: Direct the project, design the experiments and objectives, organize personnel, report progress to the DOD.

Name: Lin Li

Project Role: Senior Research Associate)

Researcher Identifier (e.g. ORCID ID): none

Nearest person month worked: 45

Contribution to Project: implantation of HCC specimens, passage of engrafted PDXs, storage of PDX engrafts.

Name: Daniel Siegwart

Project Role: Co-PI

Researcher Identifier (ORCID ID): 0000-0003-3823-1931

Nearest person month worked: 45

Contribution to Project: Co-planned and co-directed research activities. Worked on 5A2-SC8 synthesis and purification. Worked on nanoparticle delivery optimization to liver tumors.

Name: Qiang Cheng

Project Role: Senior Research Associate

Researcher Identifier (e.g. ORCID ID): none

Nearest person month worked: 45

Contribution to Project: Developed nanoparticle delivery carriers with an improved ability to deliver RNAs to the liver. Assisted with 5A2-SC8 experiments.

Name: Adam Yopp

Project Role: Co-PI

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 45

Contribution to Project: Design and conducted experiments, participated in co-PI conference calls to organize personnel and direct project.

Name: Min Zhu

Project Role: Senior Research Associate

Researcher Identifier (e.g. ORCID ID): none

Nearest person month worked: 45

Contribution to Project: implantation of HCC specimens, passage of engrafted PDXs, storage of PDX engrafts. inventory of HCC samples, preparation of genomic DNA libraries from HCC samples, data analysis, etc.

Name: Amit Singal

Project Role: Co-PI

Researcher Identifier (e.g. ORCID ID): 0000-0002-1172-3971

Nearest person month worked: 45

Contribution to Project: Design experiments, participated in co-PI conference calls to organize personnel and direct project.

Name: Veronica Renteria

Project Role: Research coordinator

Researcher Identifier (e.g. ORCID ID): none

Nearest person month worked: 33

Contribution to Project: collection of HCC specimens

Name: Amanda Ellis

Project Role: Research assistant

Researcher Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 1

Contribution to Project: Ms. Ellis has performed administrative duties such as organizing meetings, regulatory policies, and served as liaison between AAVA and UTSW.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel**

For Akbar Waljee, the following grants have become active:

IIR19-045 - 02/01/2020-01/31/2024

Effectiveness, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease

The purpose of the study is to compare rates of adverse events in Crohn's disease (CD) and ulcerative colitis (UC) and to compare rates of exacerbation in CD and UC for patients who continue on Anti-TNF originator medications to those switched to a biosimilar medication. We will also compare the accuracy and calibration of traditional regression models vs. machine learning models for predicting medication related adverse event related to Anti-TNF in VA users with CD and UC. Deliberative democratic sessions will engage Veterans to elicit their preference regarding "like" medication switch programs with and without their knowledge and to develop consensus around treatment approaches.

HX-19-008 - 02/01/2020-01/31/2024

Understanding the Role of VA Specialty Care Resource Hubs and Their Potential Impact on Access in the Era of Community Care

The VA Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act of 2018 significantly expands the number of VA-enrolled Veterans eligible to access care in the community. In the era of MISSION, how VA optimizes timely access to care in its own facilities will significantly impact the extent to which Veterans' care will be outsourced to community settings.

## What other organizations were involved as partners?

Nothing to report

### 8. SPECIAL REPORTING REQUIREMENTS

**COLLABORATIVE AWARDS:** For collaborative awards, independent reports are required from BOTH the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.

**QUAD CHARTS:** If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.

9. **APPENDICES:** Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.